ChAd63 MVA ME-TRAP

ChAd63 MVA ME-TRAP is an experimental heterologous prime-boost viral vectored vaccine candidate developed by the Jenner Institute at the University of Oxford for the prevention of malaria. The vaccine regimen consists of a priming dose of a recombinant chimpanzee adenovirus serotype 63 (ChAd63) vector, followed by a booster dose of a recombinant modified vaccinia virus Ankara (MVA) vector, both encoding the multiple epitope string thrombospondin-related adhesion protein (ME-TRAP) antigen. ME-TRAP is a hybrid antigen containing a multi-epitope string of 20 mainly CD8+ T-cell epitopes from pre-erythrocytic antigens, fused to the pre-erythrocytic thrombospondin-related adhesion protein (TRAP) from Plasmodium falciparum. This prime-boost strategy is designed to induce potent cellular immune responses, particularly antigen-specific CD8+ and CD4+ T cells, targeting the liver stage of the malaria parasite's life cycle. Although the vaccine demonstrated safety, high immunogenicity, and partial protective efficacy in Phase I and Phase IIa/IIb trials in adults, it failed to show significant protective efficacy in a Phase IIb trial in infants and young children in highly endemic regions.

Other names

ChAd63 ME-TRAP + MVA ME-TRAPChAd63 MVA ME-TRAPChAd-63 MVA ME-TRAPChAd 63 MVA ME-TRAPChAd63-MVA ME-TRAPChAd-63-MVA ME-TRAPChAd 63-MVA ME-TRAPChAd63/MVA ME-TRAP